What is the clinical evidence from this study?

Study design: Editorial. Population: Heart failure.

What question did this study set out to answer?

To synthesize key clinical findings and emerging evidence regarding novel pharmacotherapies, catheter interventions, device management, and prognostic risk stratification in heart failure.

October 1, 2016European Journal of Heart FailureOpen Access

October 2016 at a Glance: Treatment of Heart Failure

View Full Paper

Ask AI

Bookmark

Key result

This editorial highlights recent advances in heart failure treatment, reviewing studies on sacubitril/valsartan, nitrates-hydralazine, CHA2DS2-VASc scores, lead extractions, and Mitraclip therapy.

Key Points

To synthesize key clinical findings and emerging evidence regarding novel pharmacotherapies, catheter interventions, device management, and prognostic risk stratification in heart failure.
Reviewed post hoc analyses from randomized trials assessing neprilysin inhibition (PARADIGM-HF) and hydralazine/nitrate therapy in sub-Saharan Africa (BA-HEF).
Evaluated observational and trial data investigating the CHA2DS2-VASc score in sinus rhythm (WARCEF), transvenous lead extraction outcomes in cardiac resynchronization therapy, and MitraClip feasibility.
Summarized the protocol and objectives of the prospective PREFERS cohort study examining biomarkers across 2000 patients with new-onset heart failure.
In PARADIGM-HF, study drug dose reductions occurred in 42% on sacubitril/valsartan and 43% on enalapril and conferred a 2.5-fold higher risk of the primary outcome, yet the relative benefit of sacubitril/valsartan remained consistent.
In the WARCEF trial cohort, each 1-point increase in the CHA2DS2-VASc score was associated with a 21% increase in the hazard of death or ischemic stroke among heart failure patients in sinus rhythm.
Transvenous lead extraction achieved a 99.2% procedural success rate across 256 patients, though 53.9% experienced adverse events over a median follow-up of 21 months.

PICO

Population

Heart failure

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This editorial provides an overview of key heart failure research published in the October 2016 issue, highlighting advances in medical therapy, risk stratification, and device management.

Cite This Study

Marco Metra (2016) conducted an editorial in Heart failure. This editorial highlights recent advances in heart failure treatment, reviewing studies on sacubitril/valsartan, nitrates-hydralazine, CHA2DS2-VASc scores, lead extractions, and Mitraclip therapy.

synapsesocial.com/papers/6a6f3e35e5469ee92be043a9 https://doi.org/10.1002/ejhf.672

Topics

HFrEF treatment Heart failure HFpEF management Heart failure hospitalization

View Full Paper

Ask AI

Bookmark

Implication

This editorial provides an overview of key heart failure research published in the October 2016 issue, highlighting advances in medical therapy, risk stratification, and device management.

October 2016 at a Glance: Treatment of Heart Failure

Key Points

PICO

Discussion

Implication

Cite This Study

Topics

October 2016 at a Glance: Treatment of Heart Failure

Key Points

PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider